The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study

Autor: Philippe Vanhems, Claire Billioud, Michèle Chevallier, Patrick Miailhes, Fabien Zoulim, Tristan Ferry, Thomas Bénet, Corinne Brochier, André Boibieux, Laurent Cotte, Jean-Yves Scoazec
Přispěvatelé: Equipe 16, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], equipe 4, Laboratoire Central d'Anatomie et de Cytologie Pathologiques [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunité infection vaccination (I2V), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR128-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Biomnis, equipe 15, Service d'hépatologie et de gastroentérologie, Hospices Civils de Lyon (HCL)-Hôtel-Dieu-Hospices Civils de Lyon (HCL)-Hôtel-Dieu-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Université de Lyon-IFR128-Institut National de la Santé et de la Recherche Médicale (INSERM)
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Male
HIV Infections
Gastroenterology
MESH: Antiretroviral Therapy
Highly Active
0302 clinical medicine
Interquartile range
Antiretroviral Therapy
Highly Active
030212 general & internal medicine
MESH: Anti-HIV Agents
10. No inequality
Didanosine
Univariate analysis
MESH: Middle Aged
Reverse-transcriptase inhibitor
Stavudine
MESH: HIV Infections
Middle Aged
MESH: Case-Control Studies
3. Good health
MESH: Didanosine
Liver
Reverse Transcriptase Inhibitors
Female
030211 gastroenterology & hepatology
MESH: Liver Regeneration
MESH: Organophosphonates
Nodular regenerative hyperplasia
medicine.drug
Adult
medicine.medical_specialty
MESH: Adenine
Anti-HIV Agents
Organophosphonates
MESH: Stavudine
[SDV.CAN]Life Sciences [q-bio]/Cancer
03 medical and health sciences
Internal medicine
Hypertension
Portal
medicine
Humans
Tenofovir
MESH: Hypertension
Portal
Hyperplasia
MESH: Humans
Hepatology
MESH: Hyperplasia
business.industry
Adenine
Case-control study
MESH: Adult
Odds ratio
medicine.disease
MESH: Male
Liver Regeneration
Case-Control Studies
Immunology
MESH: Reverse Transcriptase Inhibitors
business
MESH: Female
MESH: Liver
Zdroj: Journal of Hepatology
Journal of Hepatology, Elsevier, 2011, 54 (3), pp.489-96. ⟨10.1016/j.jhep.2010.07.030⟩
Journal of Hepatology, 2011, 54 (3), pp.489-96. ⟨10.1016/j.jhep.2010.07.030⟩
ISSN: 0168-8278
1600-0641
DOI: 10.1016/j.jhep.2010.07.030⟩
Popis: International audience; BACKGROUND & AIMS: Nodular regenerative hyperplasia (NRH) leading to non-cirrhotic portal hypertension has been described in HIV-infected patients and has been linked to didanosine. The relation between NRH and other antiretrovirals remains unclear. METHODS: A case-control study was performed in 13 patients with NRH and 78 controls matched for time of inclusion, baseline CD4, and duration of follow-up. Univariate and multivariate conditional logistic regression analyses were performed. RESULTS: Control patients and patients with NRH were similar at baseline regarding demographics and biological data with the exception of older age for patients with NRH (43.9 vs. 33.5 years, p=0.044). At the time of NRH diagnosis, cases had a lower CD4 count (327 vs. 468/mm(3), p=0.013), a similar CD4 percentage (24 vs. 26.2%, p=0.7), a lower platelet count (169 vs. 228 giga/L, p=0.003) and a higher AST level (33 vs. 26 IU/L, p=0.001) than controls. Univariate analysis demonstrated that patients with NRH had been exposed longer than controls to didanosine, stavudine, tenofovir, didanosine+stavudine, and didanosine+tenofovir. The age at baseline [OR 2.2 (1.0-5.0) per 10 years, p=0.053] and didanosine+stavudine cumulative exposure [OR 3.7 (1.4-10.2) per year, p=0.011] were independently associated with NRH. The age at baseline [OR 2.3 (1.0-5.3) per 10 years, p=0.045], cumulative exposure to didanosine [OR 1.4 (1.1-1.9) per year, p=0.023] and to tenofovir [OR 1.7 (1.0-2.8) per year, p=0.04] were independently associated with NRH when didanosine+stavudine exposure was excluded from the model. CONCLUSIONS: NRH in HIV-infected patients seems strongly related to age and the cumulative exposure to didanosine+stavudine, didanosine, and stavudine.
Databáze: OpenAIRE
Externí odkaz: